Tekla Capital Management
51
66M
41
1.34
5
0.20
18
- Stages of investment
- Areas of investment
Summary
The main office of represented VC is situated in the Boston. The company was established in North America in United States.
We also calculated 1 valuable employee in our database.
The typical case for the fund is to invest in rounds with 7-8 participants. Despite the Tekla Capital Management, startups are often financed by Novartis Venture Fund, Domain Associates, Third Rock Ventures. The meaningful sponsors for the fund in investment in the same round are Life Sciences Partners, Sofinnova Investments, Redmile Group. In the next rounds fund is usually obtained by Sofinnova Investments, Life Sciences Partners, Ysios Capital.
The top amount of exits for fund were in 2019. The usual things for fund are deals in the range of 50 - 100 millions dollars. The real fund results show that this VC is 3 percentage points less often commits exit comparing to other companies. The fund is constantly included in less than 2 investment rounds annually. This Tekla Capital Management works on 28 percentage points more the average amount of lead investments comparing to the other organizations. The important activity for fund was in 2018.
Among the most popular portfolio startups of the fund, we may highlight Afferent Pharmaceuticals, Merus, CuraSen Therapeutics. We can highlight the next thriving fund investment areas, such as Medical, Health Care. The fund has exact preference in a number of founders of portfolio startups. When startup sums 3 of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.
Investments analytics
Analytics
- Total investments
- 51
- Lead investments
- 5
- Exits
- 18
- Rounds per year
- 1.34
- Follow on index
- 0.20
- Investments by industry
- Biotechnology (46)
- Health Care (29)
- Therapeutics (23)
- Medical (18)
- Pharmaceutical (14) Show 16 more
- Investments by region
-
- United States (37)
- Switzerland (4)
- France (2)
- Iceland (3)
- United Kingdom (1) Show 3 more
- Peak activity year
- 2021
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 12
- Avg. valuation at time of investment
- 68M
- Group Appearance index
- 1.00
- Avg. company exit year
- 14
- Avg. multiplicator
- 4.79
- Strategy success index
- 0.60
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Endeavor BioMedicines | 24 Apr 2024 | Biotechnology | Late Stage Venture | 132M | United States, California |
Parthenon Therapeutics | 03 Nov 2021 | Biotechnology, Life Science, Therapeutics | Early Stage Venture | 65M | United States, Massachusetts, Cambridge |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.